BRPI0917245A8 - Compostos derivados de isoquinolinona e sua composição farmacêutica - Google Patents

Compostos derivados de isoquinolinona e sua composição farmacêutica

Info

Publication number
BRPI0917245A8
BRPI0917245A8 BRPI0917245A BRPI0917245A BRPI0917245A8 BR PI0917245 A8 BRPI0917245 A8 BR PI0917245A8 BR PI0917245 A BRPI0917245 A BR PI0917245A BR PI0917245 A BRPI0917245 A BR PI0917245A BR PI0917245 A8 BRPI0917245 A8 BR PI0917245A8
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
derivative compounds
isoquinolinone
compounds
isoquinolinone derivative
Prior art date
Application number
BRPI0917245A
Other languages
English (en)
Inventor
Khanzhin Nikolay
Juhl Karsten
Moller Nielsen Soren
Baek Simonsen Klaus
Original Assignee
H Lundbeck As
Sojournix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41227186&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0917245(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As, Sojournix Inc filed Critical H Lundbeck As
Publication of BRPI0917245A2 publication Critical patent/BRPI0917245A2/pt
Publication of BRPI0917245A8 publication Critical patent/BRPI0917245A8/pt
Publication of BRPI0917245B1 publication Critical patent/BRPI0917245B1/pt
Publication of BRPI0917245B8 publication Critical patent/BRPI0917245B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSTOS DERIVADOS DE ISOQUINOLINONA E SUA COMPOSIÇÃO FARMACÊUTICA. A invenção refere-se aos derivados de isoquinolinona úteis em terapia, em particular no tratamento de psicose, às composições compreendendo ditos compostos, e aos métodos de tratar doenças compreendendo a administração de ditos compostos.
BRPI0917245A 2008-09-15 2009-09-11 compostos derivados de isoquinolinona e sua composição farmacêutica BRPI0917245B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200801290 2008-09-15
DKPA200801290 2008-09-15
DKPA200900010 2009-01-06
DKPA200900010 2009-01-06
PCT/DK2009/050237 WO2010028655A1 (en) 2008-09-15 2009-09-11 Isoquinolinone derivatives as nk3 antagonists

Publications (4)

Publication Number Publication Date
BRPI0917245A2 BRPI0917245A2 (pt) 2015-11-10
BRPI0917245A8 true BRPI0917245A8 (pt) 2018-08-14
BRPI0917245B1 BRPI0917245B1 (pt) 2020-07-28
BRPI0917245B8 BRPI0917245B8 (pt) 2021-05-25

Family

ID=41227186

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0917245A BRPI0917245B8 (pt) 2008-09-15 2009-09-11 compostos derivados de isoquinolinona e sua composição farmacêutica

Country Status (27)

Country Link
EP (1) EP2342182B1 (pt)
JP (1) JP5536776B2 (pt)
KR (1) KR101638641B1 (pt)
CN (1) CN102149685B (pt)
AR (1) AR073511A1 (pt)
AU (1) AU2009291309B2 (pt)
BR (1) BRPI0917245B8 (pt)
CA (1) CA2732612C (pt)
CL (1) CL2011000533A1 (pt)
CO (1) CO6351781A2 (pt)
CY (1) CY1113743T1 (pt)
DK (1) DK2342182T3 (pt)
EA (1) EA021581B1 (pt)
ES (1) ES2399177T3 (pt)
HR (1) HRP20130038T1 (pt)
IL (1) IL210236A (pt)
MX (1) MX2011001786A (pt)
MY (1) MY164998A (pt)
NZ (1) NZ591265A (pt)
PL (1) PL2342182T3 (pt)
PT (1) PT2342182E (pt)
RS (1) RS52674B (pt)
SI (1) SI2342182T1 (pt)
SM (1) SMT201300020B (pt)
TW (1) TWI454461B (pt)
WO (1) WO2010028655A1 (pt)
ZA (1) ZA201103119B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008131779A1 (en) 2007-04-26 2008-11-06 H. Lundbeck A/S Isoquinolinone derivatives as nk3 antagonists
AR072198A1 (es) 2008-06-23 2010-08-11 Lundbeck & Co As H Derivados de isoquinolinona como antagonistas de nk3 y composiciones farmaceuticas que los contienen
AR073891A1 (es) 2008-10-20 2010-12-09 Lundbeck & Co As H Derivados de isoquinolinona antagonistas de receptores nk3, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de psicosis, alzheimer y otras enfermedades.
TW201143768A (en) 2009-12-15 2011-12-16 Lundbeck & Co As H Pyridone derivatives as NK3 antagonists
TW201144311A (en) * 2010-03-12 2011-12-16 Lundbeck & Co As H Azaisoquionolinone derivatives as NK3 antagonists
BR112014011173A2 (pt) 2011-11-09 2017-05-09 Abbvie Deutschland carboxamidas heterocíclicas úteis como inibidores de fosfodiesterase tipo 10a
JP2021522341A (ja) * 2018-04-27 2021-08-30 ソージャニックス， インコーポレイテッド イソキノリノンの多形及びアモルファス形態ならびにその使用方法
WO2023152888A1 (ja) * 2022-02-10 2023-08-17 カルナバイオサイエンス株式会社 フルオロイソキノリン化合物およびその製造法
CN116621755A (zh) * 2023-05-29 2023-08-22 山东玉满坤生物科技有限公司 一种吡拉西坦有关物质的合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9825554D0 (en) * 1998-11-20 1999-01-13 Smithkline Beecham Spa Novel Compounds
EP1385839B1 (en) * 2001-04-11 2006-02-22 GlaxoSmithKline S.p.A. 3-substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
GB0509405D0 (en) * 2005-05-10 2005-06-15 Merck Sharp & Dohme Therapeutic compounds
WO2008131779A1 (en) * 2007-04-26 2008-11-06 H. Lundbeck A/S Isoquinolinone derivatives as nk3 antagonists

Also Published As

Publication number Publication date
KR101638641B1 (ko) 2016-07-11
SI2342182T1 (sl) 2013-04-30
PL2342182T3 (pl) 2013-04-30
CA2732612A1 (en) 2010-03-18
ES2399177T3 (es) 2013-03-26
BRPI0917245A2 (pt) 2015-11-10
JP2012502069A (ja) 2012-01-26
EA201170447A1 (ru) 2011-08-30
PT2342182E (pt) 2013-02-11
CO6351781A2 (es) 2011-12-20
TW201010979A (en) 2010-03-16
MX2011001786A (es) 2011-03-29
IL210236A0 (en) 2011-03-31
AU2009291309A1 (en) 2010-03-18
IL210236A (en) 2013-08-29
ZA201103119B (en) 2012-09-26
CN102149685B (zh) 2015-01-07
NZ591265A (en) 2013-02-22
EA021581B1 (ru) 2015-07-30
JP5536776B2 (ja) 2014-07-02
KR20110059849A (ko) 2011-06-07
TWI454461B (zh) 2014-10-01
CL2011000533A1 (es) 2011-08-26
MY164998A (en) 2018-02-28
EP2342182B1 (en) 2012-11-14
SMT201300020B (it) 2013-05-06
EP2342182A1 (en) 2011-07-13
BRPI0917245B1 (pt) 2020-07-28
BRPI0917245B8 (pt) 2021-05-25
AU2009291309B2 (en) 2014-07-17
CA2732612C (en) 2016-08-09
HRP20130038T1 (hr) 2013-02-28
AR073511A1 (es) 2010-11-10
RS52674B (sr) 2013-06-28
DK2342182T3 (da) 2013-02-04
WO2010028655A1 (en) 2010-03-18
CN102149685A (zh) 2011-08-10
CY1113743T1 (el) 2016-06-22

Similar Documents

Publication Publication Date Title
EA201001639A1 (ru) Композиции и способы их получения и применения
BRPI0917245B8 (pt) compostos derivados de isoquinolinona e sua composição farmacêutica
MA32161B1 (fr) Formes de rifaximine et utilisations de celles-ci
UA114726C2 (uk) 1,4-дизаміщені аналоги піридазину та способи лікування пов'язаних з дефіцитом smn станів
UA107783C2 (en) Isoindoline compounds for use in treating cancer
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
WO2010111406A3 (en) Purine derivatives useful as anti - cancer agents
IN2012DN00971A (pt)
EA201170349A1 (ru) Модуляторы mif
EA201290836A1 (ru) Связанные бис-арильные арилтриазолоны и их применение
UA107814C2 (uk) Спірооксіндольні антагоністи мdм2
AU2011328009A8 (en) Compounds and methods for treating pain
BRPI0915084B8 (pt) composto, e, composição farmacêutica
EA201000365A1 (ru) Гетероциклические амиды, пригодные для лечения злокачественного новообразования и псориаза
MX2010007683A (es) Derivados heterociclicos fusionados y metodos de uso como inhibidores de c-met.
EA201000914A1 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
GB201118656D0 (en) New compounds
CY1119410T1 (el) Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi)
MY165579A (en) Synthetic methods for spiro-oxindole compounds
EA201400392A1 (ru) ПРОИЗВОДНЫЕ 6-ЗАМЕЩЕННЫХ ТРИАЗОЛОПИРИДАЗИНОВ КАК АГОНИСТЫ Rev-Erb
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
UA107550C2 (uk) Похідні естра-1,3,5(10),16-тетраєн-3-карбоксаміду, способи їх одержання, фармацевтичні препарати, що їх містять, та їх застосування для виготовлення лікарських засобів
EA201170753A1 (ru) Налмефена гидрохлорид дигидрат
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: SOJOURNIX, INC. (US)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 28/07/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/09/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 13A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2687 DE 05-07-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.